Nucleic Acid Amplification Testing (NAAT) Market Outlook 2031
The global nucleic acid amplification testing (NAAT) market size was valued at USD 7.09 billion in 2023 and is likely to reach USD 20.68 billion by 2031, expanding at a CAGR of 12.5% during 2023 – 2031. The growth of the market is attributed to the rising demand for precision and advanced diagnosis tests.
Increasing occurrence of infectious diseases is leading to a high demand for accurate and swift diagnostic methods, which further propels the nucleic acid amplification testing (NAAT) market. NAAT has ability to precisely detect the genetic material of infectious agents.
This versatility makes it a valuable tool to use in various dangerous pandemic outbreaks, including SARS-CoV-2. Additionally, the growing prevalence of tuberculosis further fuels the demand for NAAT.
-
As per the report published by the World Health Organization on April 21, 2023, approximately 10.6 million people globally fell ill with tuberculosis (TB) in 2021. Out of these cases, 6 million were men, 3.4 million were women, and 1.2 million were children.
NAAT is a molecular biology technique used to detect and amplify the genetic material of microorganisms such as bacteria, viruses, or parasites. It is widely used in diagnosing infections and diseases that are difficult to detect through traditional methods. Additionally, this technique is utilized in personalized medicines and the forensics domain for advanced application of nucleic amplification testing.
The research reports find that the COVID-19 pandemic propelled the market. The pandemic increased global demand for NAAT, specifically COVID-19 testing solutions, to detect SARS-CoV-2. Moreover, awareness created by COVID-19 has boosted the use of nucleic acid amplification testing in other diagnostic areas, thus contributing to the market growth.
Artificial Intelligence (AI) Impact on Nucleic Acid Amplification Testing (NAAT) Market
Emergence of artificial intelligence is expected to propel the market. AI is being integrated into NAAT for various purposes, including data analysis, result interpretation, and process automation. AI algorithms are rapidly analyzing the vast amount of data produced by NAAT, for reliable disease detection. Furthermore, AI-driven diagnostic tools are helping identify specific genetic patterns associated with diseases for precise NAAT testing.
Nucleic Acid Amplification Testing (NAAT) Market Dynamics
Major Drivers
Increasing number of cancer cases is expected to drive the market. NAAT is being widely used to detect minute traces of genetic markers associated with cancer, even before physical symptoms manifest.
This early detection leads to successful treatment outcomes and helps maximize the effectiveness of therapies. Moreover, the growing death rate of cancer patients boosts the demand for the NAAT for accurate and precise diagnostics.
-
According to the report published by the World Health Organization (WHO) on February 3, 2022, states that around 10 million, or nearly one in six people in 2020, died due to cancer.
Existing Restraints
High cost associated with nucleic acid amplification is expected to hinder the market. Advanced technology and equipment used in NAAT are expensive to acquire and maintain. This financial constraint poses a challenge for healthcare providers with limited resources and reduces the widespread adoption of NAAT. Additionally, the lack of skilled people required to operate NAAT equipment and interpret results accurately, which further hampers the market.
Emerging Opportunities
Continuous advancements and innovations in diagnostics and therapies are expected to create immense opportunities for the players competing in the market. Manufacturing focuses on improving the capability of NAAT by the development of new testing methods and the discovery of new genetic markers. Furthermore, the integration of NAAT with telemedicine platforms allows patients to perform tests remotely is contributing to propelling the market.
Scope of the Nucleic Acid Amplification Testing (NAAT) Market Report
The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Nucleic Acid Amplification Testing (NAAT) Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Ligase Chain Reaction, Isothermal Nucleic Acid Amplification Technology Tests, Polymerase Chain Reaction Tests, and Others), Application (Oncology Testing, Infectious Diseases Testing, Genetic & Mitochondrial Disease Testing, and Others), and End-user (Central & Reference Laboratories, Hospital, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott; BD; Cepheid; CERTEST BIOTEC; Danaher; F. Hoffmann-La Roche Ltd; Illumina, Inc; Novartis AG; and Siemens Healthcare GmbH
|
Nucleic Acid Amplification Testing (NAAT) Market Segment Insights
Type Analysis
Based on type, the nucleic acid amplification testing (NAAT) market is divided into ligase chain reaction, isothermal nucleic acid amplification technology tests, polymerase chain reaction tests, and others. The polymerase chain reaction (PCR) tests segment is expected to hold a major market revenue share during the forecast period due to its precision in detecting specific genetic material.
PCR tests identify various genetic materials, such as viruses, bacteria, or genetic mutations associated with diseases. This reliability is crucial in healthcare, where precise diagnosis is required for effective treatment. Additionally, continuous technological innovations in PCR, including real-time PCR and digital PCR are boosting the segment.
-
On February 22, 2022, Hoffmann-La Roche Ltd, a leading provider of healthcare solutions, announced the expansion of their COVID-19 PCR portfolio to include cobas 5800 System. This molecular laboratory instrument is available in countries where the CE mark is accepted. Additionally, this new product launch is expected to enhance the Roche solutions portfolio by providing efficiencies and standardized performance across low-, medium-, and high-volume molecular laboratory testing needs.
The isothermal nucleic acid amplification technology (INAAT) tests segment is expected to expand at a significant CAGR during the forecast period owing to its simplicity and rapidity. Unlike traditional PCR tests that involve complex temperature cycling, INAAT amplifies genetic material at a constant temperature.
INAAT’s simplicity leads to faster results and straightforward testing procedures, making it highly preferable among healthcare professionals. Additionally, the introduction of new technologies, including loop-mediated isothermal amplification (LAMP) boosts the market.
Application Analysis
On the basis of application, the market is classified as oncology testing, infectious diseases testing, genetic & mitochondrial disease testing, and others. The infectious diseases testing segment is expected to hold a key market share during the projected period due to the increasing prevalence of COVID-19, hepatitis, antibiotic-resistant bacteria, and other infectious diseases.
NAAT, especially PCR and isothermal amplification techniques provide the precision to identify and monitor infectious agents accurately. Moreover, the growing number of patients seeking help healthcare for their infectious diseases further contributes to propel the demand for NAAT.
-
According to a report published by the Centers for Disease Control and Prevention on September 19, 2023, around 3.8 million people were diagnosed with infectious and parasitic diseases while visiting emergency departments. Additionally, approximately 10.2 million people visited physician's offices for infectious and parasitic diseases.
The oncology testing segment is anticipated to register robust growth during the forecast period owing to the rising occurrence of cancer cases. NAAT tests, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are being widely used for identifying genetic markers associated with various types of cancer. This ability to accurately detect these genetic alterations is important for early cancer diagnosis and tailored treatment.
End-user Analysis
In terms of end-user, the nucleic acid amplification testing (NAAT) market is fragmented into central & reference laboratories, hospital, and others. The hospital segment is projected to register a considerable CAGR during the forecast period due to its vast patient base with diverse diagnostic requirements.
Hospitals encounter cases ranging from infectious diseases to genetic disorders and cancer. NAAT's versatility in addressing various diagnostic needs propels their demand in this type of medical setting for comprehensive genetic testing services.
Regional Outlook
In terms of region, the global nucleic acid amplification testing (NAAT) market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market due to the growing prevalence of chronic diseases, such as cancer.
NAAT is widely utilized in oncology testing, offering precise genetic diagnostics that guide treatment decisions. Moreover, the presence of major companies focused on NAAT development, production, and distribution further contributes to the market growth in this region.
The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years due to the large and growing population. This wide population base creates an increasing demand for healthcare services, including advanced diagnostics. Additionally, the surge in infectious diseases, such as Hendra, Japanese encephalitis, and Nipah virus infections is boosting the demand for nucleic acid amplification testing in this region.
Segments
The global nucleic acid amplification testing (NAAT) market has been segmented on the basis of
Type
- Ligase Chain Reaction
- Isothermal Nucleic Acid Amplification Technology Tests
- Polymerase Chain Reaction Tests
- Others
Application
- Oncology Testing
- Infectious Diseases Testing
- Genetic & Mitochondrial Disease Testing
- Others
End-user
- Central & Reference Laboratories
- Hospital
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global nucleic acid amplification testing (NAAT) market are Abbott; BD; Cepheid; CERTEST BIOTEC; Danaher; F. Hoffmann-La Roche Ltd; Illumina, Inc; Novartis AG; and Siemens Healthcare GmbH.
These companies are boosting their market share by adopting various strategies such as partnerships, mergers, reduction in production costs, launching products, and implementing advanced technologies.
-
On September 26, 2022, healthcare technology provider Becton, Dickinson and Company (BD) and CERTEST BIOTEC, a biotechnology company jointly announced the commercial launch of a newly developed molecular polymerase chain reaction (PCR) assay for monkeypox virus. This technology is available worldwide, including in the US, for research applications in laboratories and other facilities.
Request For Customization
Enquiry Before Buying
Speak With Analyst
